Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02333929 · ClinicalTrials.gov registry record
Validation of Rivaroxaban Assay for US Registration
A clinical trial of Patients Receiving Rivaroxaban Treatment, sponsored by Diagnostica Stago.
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT02333929: Completed study of Patients Receiving Rivaroxaban Treatment, sponsored by Diagnostica Stago.
NCT02333929 is a study of Patients Receiving Rivaroxaban Treatment that has completed, run by Diagnostica Stago. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02333929, a study of Patients Receiving Rivaroxaban Treatment, has completed, sponsored by Diagnostica Stago.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the study is to demonstrate the performances of the STA® - Rivaroxaban Calibrator and STA® - Rivaroxaban Control in combination with the STA® - Liquid Anti-Xa to determine the quantity of rivaroxaban in plasma samples by measurement of its direct anti-Xa activity.
Conditions Studied
Interventions
- DEVICE STA- Rivaroxaban Calibrator&Control
Study Locations (1)
Pennsylvania
- Lehigh Valley Health Nrwork - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-12 |
What the finished NCT02333929 record still lists
NCT02333929 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Patients Receiving Rivaroxaban Treatment appearing as the primary indexed condition, and to 1 intervention - of which STA- Rivaroxaban Calibrator&Control is the first listed.
NCT02333929 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02333929 about?
NCT02333929 is a clinical study titled "Validation of Rivaroxaban Assay for US Registration". The objective of the study is to demonstrate the performances of the STA® - Rivaroxaban Calibrator and STA® - Rivaroxaban Control in combination with the STA® - Liquid Anti-Xa to determine the quantity of rivaroxaban in plasma samples by measurement of its direct anti-Xa activity.
What is the current status of trial NCT02333929?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2015-03. Estimated completion is 2016-12.
What conditions does trial NCT02333929 study?
This clinical trial studies the following conditions: Patients Receiving Rivaroxaban Treatment.
What interventions are being tested in trial NCT02333929?
The interventions under investigation include: STA- Rivaroxaban Calibrator&Control (DEVICE).
Who is sponsoring clinical trial NCT02333929?
This trial is sponsored by Diagnostica Stago, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02333929 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia